Leiomyosarcoma Clinical Trial
Official title:
Phase 2 Clinical Study of Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
The purpose of this research study is to determine if letrozole is effective at controlling the growth or spread of estrogen and/or progesterone receptor positive uterine leiomyosarcoma. This drug has been used in research studies for other cancers and is currently approved by the FDA for use in breast cancer. Because letrozole lowers hormone levels in the body, it may be helpful to control tumors that express hormone receptors ( ER/PR).
- Participants will take letrozole orally once a day. During the research study the
following tests and procedures will be performed:
- Visit 1 (Day 1): physical examination, vital signs and blood work
- Visit 2 (Day 43): physical examination, vital signs, blood work, CT or MRI scan
- Visit 3 (Day 85): physical examination, vital signs, blood work, CT or MRI scan
- Participants will remain on the study drug as long as they do not have any serious sife
effect and their disease does not get worse
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04535271 -
Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Leiomyosarcoma
|
Phase 2 | |
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06088290 -
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 | |
| Terminated |
NCT02940041 -
Concordance Between Sonography Amd MRI for Presurgical Diagnosis of Uterine Mesenchymal Malignant Tumors
|
||
| Completed |
NCT01442662 -
Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patient With Metastatic or Relapsed Uterine
|
Phase 2 | |
| Completed |
NCT00062868 -
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
|
Phase 1 | |
| Recruiting |
NCT04214457 -
Development of a Predictive Model for Early Differential Diagnosis of Uterine Leiomyomas and Leiomyosarcomas
|
||
| Active, not recruiting |
NCT04420975 -
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
|
Phase 1 | |
| Terminated |
NCT04099277 -
A Study of LY3435151 in Participants With Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT05548179 -
Exploring Clinical Trial Experiences of People With Leiomyosarcoma
|
||
| Recruiting |
NCT02983539 -
Detection of Circulating Tumor Cells in Patients With Sarcomas
|
||
| Completed |
NCT00093080 -
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
|
Phase 2 | |
| Active, not recruiting |
NCT04624178 -
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
|
Phase 2 | |
| Terminated |
NCT03959033 -
Patient Reported Outcome Measures (PROMs) With Trabectedin
|
||
| Recruiting |
NCT02275286 -
Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01956084 -
Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma
|
Phase 1 | |
| Completed |
NCT01426633 -
Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas
|
Phase 1 | |
| Completed |
NCT00400569 -
Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
|
Phase 2 | |
| Recruiting |
NCT05080790 -
Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma
|
Phase 2 |